Preparative isolation and purification of steroidal glycoalkaloid from the ripe berries of Solanum nigrum L. by preparative HPLC-MS and UHPLC-TOF-MS/MS and its anti-non-small cell lung tumors effects in vitro and in vivo.

作者: Fengqiang Shi , Caifang Wang , Lixue Wang , Xueying Song , Hua Yang

DOI: 10.1002/JSSC.201801165

关键词:

摘要: Overcoming epidermal growth factor receptor resistance is a critical problem that needs to be solved in clinical practice. Drugs downregulate the fatty acid synthase-epidermal will become novel treatments for non-small cell lung cancer. Solanum nigrum, extracted with water at 4°C, shows strong cytotoxic activity and inhibits tumor Lewis bearing-mice dose-dependent manner. A active compound S. solaoiacid, was successfully separated purified from nigrum by preparative high-performance liquid chromatography mass spectrometry ultra high performance time-of-flight tandem spectrometry. The IC50 of solaoiacid on cancer cells 2.3 µmol/L, which significantly lower than known steroidal glycoalkaloid. Label-free proteomics STRING Network analysis were used identify deregulated proteins treated fresh ripe fruit extracts nigrum. regulates multiple signal pathways, including pathway. downregulated 24 main direct roles biosynthesis. Both showed downregulation anti-non-small effects, thus drug treatment

参考文章(27)
Niki Karachaliou, Clara Mayo-de las Casas, Cristina Queralt, Itziar de Aguirre, Boris Melloni, Felipe Cardenal, Ramon Garcia-Gomez, Bartomeu Massuti, José Miguel Sánchez, Ruth Porta, Santiago Ponce-Aix, Teresa Moran, Enric Carcereny, Enriqueta Felip, Isabel Bover, Amelia Insa, Noemí Reguart, Dolores Isla, Alain Vergnenegre, Filippo de Marinis, Radj Gervais, Romain Corre, Luis Paz-Ares, Daniela Morales-Espinosa, Santiago Viteri, Ana Drozdowskyj, Núria Jordana-Ariza, Jose Luis Ramirez-Serrano, Miguel Angel Molina-Vila, Rafael Rosell, Spanish Lung Cancer Group, Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. JAMA Oncology. ,vol. 1, pp. 149- 157 ,(2015) , 10.1001/JAMAONCOL.2014.257
Xinlan Zhou, Xiangjiu He, Guanghui Wang, Hao Gao, Guangxiong Zhou, Wencai Ye, Xinsheng Yao, Steroidal saponins from Solanum nigrum. Journal of Natural Products. ,vol. 69, pp. 1158- 1163 ,(2006) , 10.1021/NP060091Z
Xi Wu, Li Qin, Valerie Fako, Jian-Ting Zhang, Molecular mechanisms of fatty acid synthase (FASN)-mediated resistance to anti-cancer treatments Advances in Biological Regulation. ,vol. 54, pp. 214- 221 ,(2014) , 10.1016/J.JBIOR.2013.09.004
Dalia Ercan, Hwan Geun Choi, Cai-Hong Yun, Marzia Capelletti, Ting Xie, Michael J. Eck, Nathanael S. Gray, Pasi A. Jänne, EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors. Clinical Cancer Research. ,vol. 21, pp. 3913- 3923 ,(2015) , 10.1158/1078-0432.CCR-14-2789
Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi, Shunichi Sugawara, Satoshi Oizumi, Hiroshi Isobe, Akihiko Gemma, Masao Harada, Hirohisa Yoshizawa, Ichiro Kinoshita, Yuka Fujita, Shoji Okinaga, Haruto Hirano, Kozo Yoshimori, Toshiyuki Harada, Takashi Ogura, Masahiro Ando, Hitoshi Miyazawa, Tomoaki Tanaka, Yasuo Saijo, Koichi Hagiwara, Satoshi Morita, Toshihiro Nukiwa, Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR The New England Journal of Medicine. ,vol. 362, pp. 2380- 2388 ,(2010) , 10.1056/NEJMOA0909530
Jean-Charles Soria, Yi-Long Wu, Kazuhiko Nakagawa, Sang-We Kim, Jin-Ji Yang, Myung-Ju Ahn, Jie Wang, James Chih-Hsin Yang, You Lu, Shinji Atagi, Santiago Ponce, Dae Ho Lee, Yunpeng Liu, Kiyotaka Yoh, Jian-Ying Zhou, Xiaojin Shi, Alan Webster, Haiyi Jiang, Tony S K Mok, Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial The Lancet Oncology. ,vol. 16, pp. 990- 998 ,(2015) , 10.1016/S1470-2045(15)00121-7
Keunchil Park, Chong-Jen Yu, Sang-We Kim, Meng-Chih Lin, Virote Sriuranpong, Chun-Ming Tsai, Jong-Seok Lee, Jin-Hyoung Kang, K. C. Allen Chan, Pablo Perez-Moreno, Peter Button, Myung-Ju Ahn, Tony Mok, First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer: The ASPIRATION Study JAMA Oncology. ,vol. 2, pp. 305- 312 ,(2016) , 10.1001/JAMAONCOL.2015.4921
Jia-Sui Zhang, Jie-Ping Lei, Guo-Qing Wei, Hui Chen, Chao-Ying Ma, He-Zhong Jiang, Natural fatty acid synthase inhibitors as potent therapeutic agents for cancers: A review. Pharmaceutical Biology. ,vol. 54, pp. 1919- 1925 ,(2016) , 10.3109/13880209.2015.1113995